Sonoma Pharmaceuticals (SNOA) Receives Daily News Sentiment Score of 0.11
Media headlines about Sonoma Pharmaceuticals (NASDAQ:SNOA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sonoma Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.0321748367656 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Sonoma Pharmaceuticals, Inc. (SNOA) stock RSI moves to 28.02 – Voice Of Analysts (analystsbuzz.com)
- Sonoma Pharmaceuticals, Inc. (SNOA)- Stocks Shining Bright on Wall Street – NASDAQ Times (nasdaqtimes.com)
- Sonoma Pharmaceuticals, Inc. (SNOA)- Stocks Hammered on Sluggish Data – NASDAQ Times (nasdaqtimes.com)
- Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis (finance.yahoo.com)
Sonoma Pharmaceuticals (NASDAQ:SNOA) traded up 4.28% on Friday, reaching $5.12. The company had a trading volume of 32,195 shares. The company’s 50-day moving average is $5.41 and its 200-day moving average is $6.43. The company’s market capitalization is $22.06 million. Sonoma Pharmaceuticals has a 52-week low of $3.91 and a 52-week high of $8.25.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.09). The firm had revenue of $3.84 million for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 44.24% and a net margin of 54.36%. Equities analysts anticipate that Sonoma Pharmaceuticals will post ($2.67) EPS for the current fiscal year.
SNOA has been the subject of several recent research reports. Maxim Group set a $10.00 price objective on Sonoma Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. ValuEngine downgraded Sonoma Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/10/08/sonoma-pharmaceuticals-snoa-receives-daily-news-sentiment-score-of-0-11.html.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.